Nurix Therapeutics, Inc. NRIX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Nurix Therapeutics, Inc. (NRIX) reported accretion (amortization) of discounts and premiums, investments of $1.98M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 44.4% year-over-year, from $3.56M to $1.98M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Nurix Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 82.2% compound annual growth rate (CAGR), from -$1.71M to $10.32M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income for the amortization of discounts or premiums on held-to-maturity or available-for-sale investment securities. It reflects the gradual recognition of interest income over the life of the investment, adjusting the carrying value toward par value. Investors use this to reconcile reported net income with actual cash flows generated from investment activities.